Concepedia

Drew Neavin

DN

22

Publications

1.1K

Citations

18

H-Index

2016

Active since

Affiliations

Mayo Clinic(Current)

Garvan Institute of Medical Research

UNSW Sydney

WinnMed

Duke University

Drew Neavin is an author at Mayo Clinic specializing in medicine, pharmacology, and pharmacogenomics.

ORCID

Top concepts

Publications per year

2016–2024

22

Publications

22

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics

M Gupta, Drew Neavin, Duan Liu et al. · Molecular Psychiatry · 2016 · 116 citations · Full text

, , +20

Single cell eQTL analysis identifies cell type-specific genetic control of gene expression in fibroblasts and reprogrammed induced pluripotent stem cells

Drew Neavin, Quan Nguyen, Maciej Daniszewski et al. · Genome biology · 2021 · 112 citations · Full text

Pharmacogenomics‐Driven Prediction of Antidepressant Treatment Outcomes: A Machine‐Learning Approach With Multi‐trial Replication

Arjun P. Athreya, Drew Neavin, Tania Carrillo‐Roa et al. · Clinical Pharmacology & Therapeutics · 2019 · 105 citations · Full text

Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression

Siamak MahmoudianDehkordi, Ahmed T. Ahmed, Sudeepa Bhattacharyya et al. · Translational Psychiatry · 2021 · 93 citations · Full text

Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients

Sudeepa Bhattacharyya, Ahmed T. Ahmed, Matthias Arnold et al. · Translational Psychiatry · 2019 · 80 citations · Full text

Rows per page

1–5 of 22